Close

Upsher-Smith launches new prenatal vitamin

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...
- Advertisement -

Upsher-Smith Laboratories has launched B-Nexa, a prescription prenatal vitamin for pregnant women who suffer from nausea and vomiting of pregnancy (NVP).

B-Nexa is designed with B vitamins and ginger to help calm NVP, also known as morning sickness, the most common symptom of pregnancy, the company said. Taken once or twice daily, B-Nexa contains vitamin B6 and ginger to help calm nausea and vomiting during pregnancy. Each antihistamine-free tablet also contains 1.2mg folic acid.

Upsher-Smith medical affairs senior director Wesley Todd said that B-Nexa is a new option in the prenatal nutrition market that has been designed to help calm nausea and vomiting of pregnancy.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Eli Lilly’s $3.5 Billion Manufacturing Campus Advances in Upper Macungie, Pennsylvania

A planned $3.5 billion pharmaceutical manufacturing campus in Upper...

Overcoming Resistance-Associated Substitutions (RASs) to Direct-Acting Antivirals

Alt tag: Scientific illustration of Hepatitis C virus interacting...

Genentech Completes Structural Framework at New NC Manufacturing Facility

Genentech raised the final beam of its new Holly...

Chugai Pharmaceutical and GSK Sign Exclusive License Agreement for Anti-Dengue Antibody AID351

Japan-based Chugai Pharmaceutical has entered into an exclusive license...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »